This is also true in other tumour lineages, such as CRC; however, whereas increased BIM and BMF primed CRC cells to undergo substantial apoptosis following treatment with the BCL2/BCL-w/BCL-XL inhibitor navitoclax/ABT-26311,25,26, this combination was notably less effective in melanoma11,27,28. This evidence concerns the gene BCL2L11 and neoplasm.